SMART drives highest quality data and compliance by unleashing data transparency, synchronous communication
Bioclinica®, a global life sciences services provider that utilizes science and technology to bring clarity to clinical trials, today introduces its expanded and enhanced SMART technology suite available with Medical Imaging, Electronic Data Capture (EDC) and Interactive Response Technology (IRT) combined. Bioclinica’s proven, synchronous clinical trial technologies converge all essential activities in a common data set. Investigative sites can now access Medical Imaging, EDC and IRT data via a single, easy-to-use portal where they can view, analyze and act on the data. Implementation is underway by a major pharmaceutical company and a leading CRO who are using Bioclinica’s enhanced SMART technology for their global trial portfolio.
“Our clients are already using our best-in-class SMART technology suite to Submit, Manage, Analyze, Report and Transfer medical image data compliant with global data privacy and regulatory requirements. With these new enhancements, we’re providing sponsors and CROs a catalyst to effectively and efficiently consume data throughout the trial,” says Bioclinica President & CEO David Herron. “By allowing sites to see these critical activities together, SMART eliminates cumbersome reconciliation steps and rework, creating tangible value in efficiency, quality and compliance along the data chain of custody.”
“Data transparency with real-time data reconciliation capability from start to finish is a real game-changer for our clients and their trials,” says Bioclinica’s Chief Information Officer Gavin Nichols. “SMART erases boundaries that separate processes and information.”
Additional benefits of the enhanced SMART technology suite include:
- Real-time data reconciliation: Eliminates site re-work, duplicate data entry and queries between systems – all of which slow database lock.
- : Replaces inefficient manual methods of query resolution.
- Reduced data management effort and faster database lock: Allows sites to skip these data cleaning steps since information is automatically and continuously updated and scrubbed. This prevents downstream errors that can potentially impact data quality and compliance.
- Using SMART with Bioclinica’s rapid-start IRT: Gives clients a prototype patient screening, enrollment and dispensing system within days of protocol receipt.
SMART allows plug-in functionality with Bioclinica Site & Patient Payments, Cardiac Safety (ECG and ABPM), and Clinical Event Adjudication, as well as third-party providers.
SMART was developed through collaboration among Bioclinica technology developers and in-house medical experts with input from industry-leading life sciences companies. “The result is clinical trial technology with the flexibility to adapt to clients’ needs regardless of the size or complexity of the study protocol,” Herron explains. “Our end goal is enabling sponsors and CRO partners with better management and execution of more highly complex clinical trials on a global scale.”
Earlier this year, Clinical Informatics News recognized Bioclinica SMART with a Best Practices Award for Innovation in Patient Data Management.
Bioclinica will preview SMART at the DIA Annual Global Meeting in Boston on June 25-27 where the company is exhibiting and presenting. Anyone interested is invited to schedule a one-on-one meeting during DIA or another time.
Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.